[go: up one dir, main page]

MA40657A1 - Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci - Google Patents

Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci

Info

Publication number
MA40657A1
MA40657A1 MA40657A MA40657A MA40657A1 MA 40657 A1 MA40657 A1 MA 40657A1 MA 40657 A MA40657 A MA 40657A MA 40657 A MA40657 A MA 40657A MA 40657 A1 MA40657 A1 MA 40657A1
Authority
MA
Morocco
Prior art keywords
pemetrexed
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
stable pharmaceutical
Prior art date
Application number
MA40657A
Other languages
English (en)
Other versions
MA40657B2 (fr
Inventor
Mi-Won Sohn
Sun-Woo Jang
Dong-Han Won
Yong-Min Kim
Hyung-Don Hwang
Dong-Hun Min
Original Assignee
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A St Co Ltd filed Critical Dong A St Co Ltd
Publication of MA40657A1 publication Critical patent/MA40657A1/fr
Publication of MA40657B2 publication Critical patent/MA40657B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition d'une solution injectable prête à l'emploi comprenant du pemetrexed ou des sels pharmaceutiquement acceptables de ceux-ci, comprenant : du pemetrexed ; du sulfite de sodium anhydre ; et de la n-acétyl-l-cystéine. Relativement à une utilisation en tant que préparation injectable, la composition d'une solution injectable prête à l'emploi comprenant le pemetrexed de la présente invention est appropriée pour une administration efficace de pemetrexed étant donné q
MA40657A 2014-11-17 2015-11-06 Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci MA40657B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140160225A KR101770605B1 (ko) 2014-11-17 2014-11-17 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
PCT/KR2015/011905 WO2016080687A1 (fr) 2014-11-17 2015-11-06 Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci

Publications (2)

Publication Number Publication Date
MA40657A1 true MA40657A1 (fr) 2018-06-29
MA40657B2 MA40657B2 (fr) 2021-10-29

Family

ID=56014166

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40657A MA40657B2 (fr) 2014-11-17 2015-11-06 Composition pharmaceutique stable comprenant du pemetrexed ou un sel pharmaceutiquement acceptable de celui-ci

Country Status (6)

Country Link
US (1) US20170340638A1 (fr)
EP (1) EP3222271A4 (fr)
JP (1) JP6236165B2 (fr)
KR (1) KR101770605B1 (fr)
MA (1) MA40657B2 (fr)
WO (1) WO2016080687A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60103512T2 (de) * 2000-02-04 2005-06-02 Eli Lilly And Co., Indianapolis Pharmazeutische zusammensetzung enthaltend pemetrexed zusammen mit monothioglycerol, l-cystein oder thioglykolsäure
US9655898B2 (en) 2010-07-28 2017-05-23 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
KR20130122065A (ko) * 2012-04-30 2013-11-07 씨제이제일제당 (주) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
KR101260636B1 (ko) 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제

Also Published As

Publication number Publication date
WO2016080687A1 (fr) 2016-05-26
KR101770605B1 (ko) 2017-08-23
EP3222271A4 (fr) 2018-05-16
JP2017504646A (ja) 2017-02-09
MA40657B2 (fr) 2021-10-29
KR20160058564A (ko) 2016-05-25
EP3222271A1 (fr) 2017-09-27
JP6236165B2 (ja) 2017-11-22
US20170340638A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX392213B (es) Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
MX2019003790A (es) Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
EA201892119A1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
MA43828B1 (fr) Agents thérapeutiques pour maladies neurodégénératives
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA52424B1 (fr) Compositions pharmaceutiques comprenant du (2s)--((1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl)-1,4-oxazepane-2-carboxamide
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA201690888A1 (ru) Новые гетероциклические соединения
MA38358A1 (fr) Formulations de composés organiques
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201992542A1 (ru) Фармацевтическая композиция для местного применения, содержащая, по меньшей мере, амитриптилин, для лечения периферической нейропатической боли
EA201890532A1 (ru) Новые аннелированные бензамиды
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
EA201692298A1 (ru) Производные карбоксамидов
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
PH12022551415A1 (en) Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение